In addition, recent studies have demonstrated the potential to differentiate among synucleinopathy subtypes (such as MSA from PD) based on synuclein deposition and regional topography, although it is unclear if this has been incorporated into clinical decision making (19–21). This evidence concerns the gene SNCA and Parkinson disease.